Table 1.

Characteristics of the Study Cohort

Characteristic	Counts	%	Developed Active TB
			Total	2 Years	5 Years
All	37 163	100	329	126	198
Age at migration, y
≤14	4334	11.7	15	8	9
15–34	19 510	52.5	132	64	94
35–75	13 319	35.8	156	54	95
Country of birth TB incidence (per 100 000)
0–9	455	1.2	2	1	2
10–29	2612	7.0	4	2	4
30–49	2273	6.1	5	4	5
50–99	6123	16.5	19	13	15
100–199	9805	26.4	87	36	56
200+	15 877	42.7	186	70	116
Sex
Male	13 379	36.0	142	53	89
Female	23 784	64.0	161	73	109
Test resultsa
TST 5–9 mm	4860	13.08	13	4	7
TST 10–14 mm	14 801	39.83	83	31	50
TST 15+mm	15 437	41.54	197	84	132
IGRA negative	3214	8.6	2	1	2
IGRA positive	636	1.7	9	6	8
BCGb
Never vaccinated	15 054	40.5	184	56	105
Vaccinated age <2 years	21 188	57.0	117	69	91
Vaccinated age ≥2 years	921	2.5	2	1	2
Recent contact
None	32 001	86.1	253	104	168
Close	1983	5.3	29	12	17
Casual	3179	8.6	21	10	13
Recent TST conversion
No	36 357	97.8	303	126	198
Yes	806	2.2	0	0	0
Carcinoma of the head and neck
No	37 145	99.9	303	126	198
Yes	18	0.1	0	0	0
Dialysis
No	36 962	99.5	300	124	196
Yes	201	0.5	3	2	2
Diabetes
No	35 134	94.5	281	115	182
Yes	2029	5.5	22	11	16
Human immunodeficiency virus
No	37 109	99.9	300	124	195
Yes	54	0.2	3	2	3
Transplantation
No	37 137	99.9	303	126	198
Yes	26	0.1	0	0	0
Treated with glucocorticoids
No	36 743	98.9	298	124	196
Yes	420	1.1	5	2	2
Treated with tumor necrosis factor
No	37 143	99.9	301	125	196
Yes	20	0.1	2	1	2

Abbreviations: IGRA, interferon gamma release assay; TB, tuberculosis; TST, tuberculin skin test.

^aSum of counts will not be equal to the overall count (n = 36 173) as 44.5% of individuals with negative IGRA results had no previous TST results, while 8.0%, 28.1%, and 19.4% had previous TST results of 5–9 mm, 10–14 mm, and 15+ mm, respectively. TST data from those with positive IGRA results were not considered, consistent with the TSTin3D’s algorithm.

^bBCG vaccination for all individuals was inferred from vaccination policies in the country and year of birth, as reported in the BCG World Atlas [13].